BLRX - BioLineRx Ltd.
| Previous Close | 2.7200 |
| Open | 2.7200 |
| Bid | 2.7500 x 900 |
| Ask | 2.7900 x 2900 |
| Day's Range | 2.7200 - 2.7708 |
| 52 Week Range | 2.3200 - 15.1500 |
| Volume | 21,921 |
| Avg. Volume | 56,942 |
| Market Cap | 28.224M |
| Beta (3Y Monthly) | 2.86 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.8350 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.00 |
- Zacks
BioLineRx Begins Part 2 of Phase I/IIa Study on Solid Tumors
BioLineRx (BLRX) starts dosing the first patient in the part 2 of the phase I/IIa study evaluating AGI-134 for solid tumors.
- PR Newswire
BioLineRx Announces Dosing of First Patient in Part 2 of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors
TEL AVIV, Israel, Sept. 25, 2019 /PRNewswire/ -- BioLineRx Ltd. (BLRX) and (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology, announced today dosing of the first patient in part 2 of the Phase 1/2a clinical study for AGI-134, a novel compound that evokes a direct anti-tumor response, as well as a vaccine effect, via a unique, multi-arm mechanism that targets patient-specific tumor neoantigens. "Following the successful completion of part 1 of the study and determination of the recommended dose, we are pleased to announce the initiation of part 2 of the Phase 1/2a study of AGI-134, our second lead oncology product," said Philip Serlin, Chief Executive Officer of BioLineRx. "In preclinical trials, AGI-134 led to regression of established primary tumors, prevented growth of secondary tumors, and triggered a vaccine effect that may prevent the development of future metastases.
- Benzinga
The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 3) Ardelyx Inc (NASDAQ: ARDX ) ( reported positive results ...
- PR Newswire
BioLineRx Successfully Completes Dose-Escalation Part of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors
TEL AVIV, Israel, Sept. 3, 2019 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that it has successfully completed the dose-escalation part of the Phase 1/2a clinical study for AGI-134, a novel compound that evokes a direct anti-tumor response, as well as a vaccine effect, via a unique, multi-arm mechanism that targets patient-specific tumor neoantigens. The maximal tolerated dose was not reached and the recommended dose for part 2 of the study was determined. The ongoing Phase 1/2a study is a multicenter, open-label study expected to take place at approximately 15 sites in the US, UK and Israel.
- PR Newswire
BioLineRx Reports Second Quarter 2019 Financial Results and Provides Corporate Update
On track for Phase 2 data read-out in pancreatic cancer by year-end 2019 Management to hold conference call today, August 6, at 10:00 am EDT TEL AVIV, Israel , Aug. 6, 2019 /PRNewswire/ -- BioLineRx Ltd. ...
- Zacks
Tenet Healthcare (THC) Q2 Earnings: What's in the Cards?
Tenet Healthcare's (THC) second-quarter earnings are likely to suffer due to lower revenues.
- PR Newswire
BioLineRx to Report Second Quarter 2019 Results on August 6, 2019
TEL AVIV, Israel, July 30, 2019 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended June 30, 2019 on Tuesday, August 6, 2019, before the US markets open. The Company will host a conference call on Tuesday, August 6, 2019 at 10:00 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. The conference call will be available via webcast and can be accessed through the Investor Relations page of BioLineRx's website.
- PR Newswire
BioLineRx Announces Change in Ratio of American Depositary Shares to Ordinary Shares
TEL AVIV, Israel, June 28, 2019 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Board of Directors has approved a change in the number of its ordinary shares represented by American Depositary Shares, issued by the Bank of New York Mellon as depositary, from 1 ordinary share per ADS to 15 ordinary shares per ADS. The change in exchange ratio for the ADSs will have the same effect as a 1-for-15 reverse stock split of the ADSs. The ADSs will continue to trade on the Nasdaq Capital Market.
- PR Newswire
BioLineRx to Present at the JMP Securities 2019 Life Sciences Conference
TEL AVIV, Israel , June 13, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Chief Executive Officer, ...
- Zacks
BioLineRx (BLRX) Moves to Buy: Rationale Behind the Upgrade
BioLineRx (BLRX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- PR Newswire
BioLineRx Reports First Quarter 2019 Financial Results and Provides Corporate Update
On track for Phase 2 data read-outs in pancreatic cancer and consolidation AML by year-end 2019 Management to hold conference call today, May 14, at 10:00 am EDT TEL AVIV, Israel , May 14, 2019 /PRNewswire/ ...
- PR Newswire
BioLineRx to Report First Quarter 2019 Results on May 14, 2019
Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel , May 7, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced ...
- PR Newswire
BioLineRx Announces FDA Approval of IND Application for AGI-134, a Novel Immunotherapy Anti-Cancer Vaccine for Solid Tumors
TEL AVIV, Israel, May 7, 2019 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AGI-134, a novel immunotherapy anti-cancer vaccine for solid tumors. "We are pleased with the FDA's IND approval, which will enable us to expand our ongoing Phase 1/2a study, currently being carried out in the UK and Israel, to the US by the first half of 2020," said Philip Serlin, Chief Executive Officer of BioLineRx.
- ACCESSWIRE
Biotech News, What Milestones and Catalysts Could Drive BioLineRx Shares in 2019
NEW YORK, NY / ACCESSWIRE / May 1, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report ...
- PR Newswire
BioLineRx Reports Year End 2018 Financial Results and Provides Corporate Update
BL-8040 and AGI-134 oncology programs progressing, with multiple data read-outs expected in the next 12 months Management to hold conference call today, March 28, at 10:00 am EDT TEL AVIV, Israel , March ...
- ACCESSWIRE
Four Tech Stocks Sparking Activity on Wednesday
Companies across the tech industry are pulling out all the stops to allocate resources for the development of innovative technology. Nowadays, consumers are outwardly vocal about the products they are interested in, and some companies in the tech sector have managed to meet the growing demands of consumers in the tech market. All in all, the future is largely unpredictable, but if the tech industry continues to develop exciting, advanced products and services to improve our quality of life, this could catalyze serious investor attention.
- PR Newswire
BioLineRx Announces Successful Engraftment Data From Phase 3 GENESIS Trial for BL-8040 in Multiple Myeloma Patients
TEL AVIV, Israel, March 27, 2019 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that hematopoietic stem cells (HSCs) mobilized by BL-8040 in combination with granulocyte colony-stimulating factor (G-CSF) were successfully engrafted in all 11 patients participating in the Part 1, lead-in period of the GENESIS trial, a double-blind, placebo-controlled Phase 3 trial comparing BL-8040 and G-CSF to G-CSF alone, in mobilization of HSCs for autologous transplantation in multiple myeloma patients. "Autologous HSC transplantation in multiple myeloma has been shown to improve overall survival compared to conventional chemotherapy.
- PR Newswire
BioLineRx to Report Annual 2018 Results on March 28, 2019
Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel , March 21, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on ...
- PR Newswire
BioLineRx to Present at the 29th Annual Oppenheimer Healthcare Conference
TEL AVIV, Israel , March 14, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Chief Executive Officer, ...
- PR Newswire
BioLineRx Announces Closing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants
TEL AVIV, Israel, Feb. 8, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has closed its previously announced underwritten public offering of 28,000,000 American Depositary Shares ("ADSs"), each representing one of its ordinary shares, and warrants to purchase 28,000,000 ADSs, at a public offering price of $0.55 per ADS and accompanying warrant. The Company in-licenses novel compounds, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.
- PR Newswire
BioLineRx Announces Pricing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants
TEL AVIV, Israel, Feb. 6, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has priced an underwritten public offering of 28,000,000 American Depositary Shares ("ADSs"), each representing one of its ordinary shares, and warrants to purchase 28,000,000 ADSs, at a public offering price of $0.55 per ADS and accompanying warrant. Copies of the final prospectus supplement may also be obtained, when available, from Oppenheimer & Co. Inc., 85 Broad St., 26th Floor, New York, New York 10004, Attention: Syndicate Prospectus Department, or by telephone: (212) 667-8055 or by email: EquityProspectus@opco.com.
- ACCESSWIRE
Biotech on the Brink of Breaking Out
HENDERSON, NV / ACCESSWIRE / February 5, 2019 / Below are some healthcare plays starting to gain investor interest that could breakout at any time. Do your research now. One of the best examples of the ...
